1 Setchell, KD (1998) Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 68, 1333S–1346S.
2 Hwang, CS, Kwak, HS, Lim, HJ, et al. (2006) Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. J Steroid Biochem Mol Biol 101, 246–253.
3 Lichtenstein, AH (1998) Soy protein, isoflavones and cardiovascular disease risk. J Nutr 128, 1589–1592.
4 Nagata, C (2000) Ecological study of the association between soy product intake and mortality from cancer and heart disease in Japan. Int J Epidemiol 29, 832–836.
5 Setchell, KD, Clerici, C, Lephart, ED, et al. (2005) S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 81, 1072–1109.
6 Schmitt, E, Dekant, W & Stopper, H (2001) Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol In Vitro 15, 433–439.
7 Lampe, JW, Skor, HE, Li, S, et al. (2001) Wheat bran and soy protein feeding do not alter urinary excretion of the isoflavan equol in premenopausal women. J Nutr 131, 740–744.
8 Rowland, IR, Wiseman, H, Sanders, TA, et al. (2000) Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 36, 27–32.
9 Duncan, AM, Merz-Demlow, BE, Xu, X, et al. (2000) Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol Biomarkers Prev 9, 581–586.
10 Atkinson, C, Newton, KM, Bowles, EJ, et al. (2008) Demographic, anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-metabolizing phenotypes among premenopausal women in the United States. Am J Clin Nutr 87, 679–687.
11 Song, KB, Atkinson, C, Frankenfeld, CL, et al. (2006) Prevalence of daidzein-metabolizing phenotypes differs between Caucasian and Korean American women and girls. J Nutr 136, 1347–1351.
12 Watanabe, S, Yamaguchi, M, Sobue, T, et al. (1998) Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr 128, 1710–1715.
13 Arai, Y, Uehara, M, Sato, Y, et al. (2000) Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol 10, 127–135.
14 Setchell, KD, Brown, NM & Lydeking-Olsen, E (2002) The clinical importance of the metabolite equol – a clue to the effectiveness of soy and its isoflavones. J Nutr 132, 3577–3584.
15 Frankenfeld, CL, McTiernan, A, Aiello, EJ, et al. (2004) Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. Cancer Epidemiol Biomarkers Prev 13, 1156–1162.
16 Frankenfeld, CL, McTiernan, A, Thomas, WK, et al. (2006) Postmenopausal bone mineral density in relation to soy isoflavone-metabolizing phenotypes. Maturitas 53, 315–324.
17 Lundh, TJ, Pettersson, H & Kiessling, KH (1988) Liquid chromatographic determination of the estrogens daidzein, formononetin, coumestrol, and equol in bovine blood plasma and urine. J Assoc Off Anal Chem 71, 938–941.
18 Setchell, KDR & Cole, SJ (2006) Method of defining equol-producer status and its frequency among vegetarians. J Nutr 136, 2188–2193.
19 Moore, WE & Moore, LH (1995) Intestinal floras of populations that have a high risk of colon cancer. Appl Environ Microbiol 61, 3202–3207.
20 Cassidy, A, Brown, JE, Hawdon, A, et al. (2006) Factors affecting the bioavailability of soy isoflavones in humans after ingestion of physiologically relevant levels from different soy foods. J Nutr 136, 45–51.
21 Hopkins, MJ & Macfarlane, GT (2002) Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 51, 448–454.
22 Hopkins, MJ, Sharp, R & Macfarlane, GT (2001) Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut 48, 198–205.
23 Sacks, FM, Lichtenstein, A, Van Horn, L, et al. (2006) Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 113, 1034–1044.
24 Kreijkamp-Kaspers, S, Kok, L, Bots, ML, et al. (2005) Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women. Am J Clin Nutr 81, 189–195.
25 Fang, J & Alderman, MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 283, 2404–2410.
26 Zhang, B, Chen, YM, Huang, LL, et al. (2008) Greater habitual soyfood consumption is associated with decreased carotid intima-media thickness and better plasma lipids in Chinese middle-aged adults. Atherosclerosis 198, 403–411.
27 Howes, JB, Sullivan, D, Lai, N, et al. (2000) The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of post menopausal women with mild to moderate hypercholesterolaemia. Atherosclerosis 152, 143–147.